[Updated and corrected, 11:50 am, 10/25/10] Solx, a Sudbury, MA-based medical device company developing a treatment system for glaucoma, has pulled in $3.7 million of an equity offering that could total $7.2 million, an SEC filing reveals. [Editors‘ Note: we originally cited Solx as being based in Medway, MA, but that is the PO box of the company. Its operations are in Sudbury.] Members of MVM Life Science Partners have seats on the Solx board of directors, according to the filing. Solx, which launched in 2000 and worked out of the business accelerator program at Boston University’s Photonics Center for four years, operated as a subsidiary of Canadian firm OccuLogix (NASDAQ: [[ticker:OCCX]]) from 2006 to December 2007, when Solx founder Doug Adams reacquired control of the company. Solx’s products for treating glaucoma include a shunt, a laser, and a sensor.
Author: Erin Kutz
Erin Kutz has a background in covering business, politics and general news. She holds a bachelor’s degree in journalism from Boston University. Erin previously worked in the Boston bureau of Reuters, where she wrote articles on the investment management and mutual fund industries. While in college, she researched for USA Today reporter Jayne O’Donnell’s book, Gen Buy: How Tweens, Teens and Twenty-Somethings Are Revolutionizing Retail. She also spent a semester in Washington, DC, reporting Capitol Hill stories as a correspondent for two Connecticut newspapers and interning in the Money section of USA Today, where she assisted with coverage on the retail and small business beats. Erin got her first taste of reporting at Boston University’s independent student newspaper, as a city section reporter and fact checker and editor of the paper’s weekly business section.
View all posts by Erin Kutz
